The community speaks

Every year, our program includes keynote speeches by some of the top thinkers and trend-makers in pharma, biotech, medtech, digital health, investment & funding, regulatory.

NLSDays features company presentations organised into tracks that interest specific audiences and fields, for example: pharma and biotechnology in R&D, therapeutics or diagnostics, academic and startup innovators, services providers.

Super Sessions address hot topics in science, business development and market strategies.

In between all of these delightful speaking events, we make sure everyone is refreshed by a classic Swedish ‘fika’ – all that your heart desires, plus lots of coffee.

Ms. Niina Aagaard

Chief Operating Officer, Nordic Innovation

20 Apr 11:00 Super Session 1

Dr. Mervi Aavikko

Project Manager FinnGen, University of Helsinki

20 Apr 11:00 Super Session 1

Dr. Ingrid Teigland Akay

Managing Partner, Hadean Ventures

21 Apr 09:15 Super Session 4

Dr. Jacqueline Ameri

CEO, Pancryos

20 Apr 09:30 Opening Plenary

View profile

Dr. Jacqueline Ameri

CEO, Pancryos

Unique Danish funding opportunities for promising and emerging innovations were essential to our early establishment and growth. Likewise, NLSDays is a unique platform that brings together the entire Nordic life science community, not only giving us the possibility of connecting with a relevant VC and Pharma community, but also helping us to establish new partnerships across the Nordic region,

 

PanCryos, a spinout from the Novo Nordisk Foundation Center for Stem Cell Biology at the University of Copenhagen, is devoted to improve the quality of life for the millions of people suffering from type 1 diabetes. The company is developing a best-in-class stem cell derived allogeneic cell therapy (PanINSULA™) that will provide the same glucose control as the pancreatic islet: sensing changes in blood glucose and producing Insulin Naturally. pancryos.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Sonia Benhamida

Senior Vice President Healthcare, DNB

21 Apr 09:15 Super Session 4

Mr. Karl Bergman

CEO, Elypta

21 Apr 11:00 Super Session 5

Dr. Magnus Björsne

CEO, Astrazeneca BioVentureHub

21 Apr 14:00 Super Session 6

Ms. Jeanne Bolger

Corporate Venture Capital Investor, Johnson & Johnson Innovation

21 Apr 09:15 Super Session 4

Dr. Nikolai Brun

Chair HMA-EMA Taskforce on Big Data

20 Apr 11:00 Super Session 1

Dr. Dina Chaya

Partner, NeoMed Management - Advisor, Omega Funds

21 Apr 09:15 Super Session 4

Mr. Stephan Christgau

Founding & Managing Partner, Eir Ventures

21 Apr 09:15 Super Session 4

Ms. Karin Conde-Knape

CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk

21 Apr 11:00 Super Session 5

Dr. Eric De La Fortelle

Venture Partner Seventure Partners

20 Apr 14:00 Super Session 2

Mr. Olivier Duchamp

Managing Director, NLSDays - NLS Invest

20 Apr 09:30 Opening Plenary

Dr. Falk Ehmann (TBC)

Chair Innovation Task Force, European Medicines Agency

Mr. Bogi Eliasen

Director of Health, Copenhagen Institute for Futures Studies

20 Apr 11:00 Super Session 1

Mr. Erik Gatenholm

CEO and Co-Founder, Cellink

20 Apr 09:30 Opening Plenary

View profile

Mr. Erik Gatenholm

CEO and Co-Founder, Cellink

It’s a great pleasure to speak and network with other entrepreneurs, business leaders, and innovators during the NLSDays 2021. The life science industry is going through a major revolution and what brought us here won’t bring us to the future we want to achieve. In the name of being able to create the future of medicine together, we need to learn to work together, to establish fruitful collaborations – and  that can only be done if we learn to share our stories, ideas, and get to work,

 

In 2016, Cellink commercialized the world’s first universal bioink, the first of many milestones in becoming the world’s leading bioprinting company. In 2020, after 3 successful acquisitions and multiple successful products launched, a bigger idea developed. With the combination of cutting-edge engineering, big data and AI initiatives, and biology, the first bio-convergence company has now emerged. www.cellink.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Gianfranco Grompone

Chief Scientific Officer, BioGaia

20 Apr 14:00 Super Session 2

Ms. Carolina Haefliger

VP, Head Centre for Genomics Research, AstraZeneca

21 Apr 11:00 Super Session 5

Dr. Abdel Halim

KOL on biomarkers, precision medicine and companion diagnostics, Biomarker Consult

21 Apr 11:00 Super Session 5

Dr. Deborah Harland

Partner at SR One - GSK Venture Capital Group

21 Apr 09:15 Super Session 4

Dr. Rafiq Hasan

CEO, ExACT Therapeutics

20 Apr 09:30 Opening Plenary

View profile

Dr. Rafiq Hasan

CEO, ExACT Therapeutics

NLSDays 2021 is a great opportunity to learn about the strong innovation emerging from the Nordics, as well as to share experiences and best practices,”

 

EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Jutta Heix

Head of International Affairs, Oslo Cancer Cluster

21 Apr 11:00 Super Session 5

Ms. Kaisa Helminen

Chief Operating Officer, Aiforia Technologies

20 Apr 09:30 Opening Plenary

View profile

Ms. Kaisa Helminen

Chief Operating Officer, Aiforia Technologies

“As global healthcare systems and organizations are adopting digital technologies such as AI at an ever increasing pace, it is crucial for us as the providers of these transformative solutions to collaborate with each other as well as with the medical professionals adopting these technologies. NLSDays provides that platform for us to share and communicate our vision by bringing together industry leaders across a wide array of fields,”

 

Aiforia’s mission is to provide the most powerful tools for AI-assisted analysis to enhance the translation of medical images into data and discoveries in all realms of healthcare. From scientific research to clinical diagnostics, Aiforia aims to outfit healthcare professionals with the digital solutions they need for the shifting landscape of medicine. www.aiforia.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Mr. Torbjörn Hägglöf

Artificial Intelligence Business Sales & Delivery Executive, Cognitive Business Solutions, IBM Global Business Services

21 Apr 14:00 Super Session 6

Dr. Frederik Knud Nielsen

Strategic Pipeline Lead, Nordics, Novartis

20 Apr 11:00 Super Session 1

Ms. Sarah Lidé

Senior Strategy & Project Manager, Medicon Valley Alliance

20 Apr 14:00 Super Session 2

Mr. Emmanuel Ligner

CEO & President at Cityva (former GE Healthcare Life Sciences)

20 Apr 09:30 Opening Plenary

Dr. Elisabeth Liljensten

CEO, Devicia

21 Apr 14:00 Super Session 6

Dr. Lars Lindsköld

Portfolio manager, Sweper / Swelife

20 Apr 11:00 Super Session 1

Dr. Joanne M. Hackett

General Partner Healthcare, IZY Capital

21 Apr 09:15 Super Session 4

Ms. Rachel Mears

Deputy Director General, Jet Capital

21 Apr 09:15 Super Session 4

Ms. Rajji Mehdwan

Head of People and Culture, Roche

20 Apr 11:00 Super Session 1

Dr. Mirjam Mol-Arts

Chief Science and Medical Officer, Ferring Pharmaceuticals

20 Apr 14:00 Super Session 2

Dr. Henrik Bjørn Nielsen

Chief Scientific Officer, Clinical Microbiomics

20 Apr 14:00 Super Session 2

Ms. Sofia Nordgren

Director of Regulatory Affairs, Devicia

21 Apr 14:00 Super Session 6

Dr. Sam Oddsson

Chief Medical Officer & Co-Founder, SidekickHealth

21 Apr 14:00 Super Session 6

Mr. Martin Olovsson

CEO and Co-Founder, Ondosis

21 Apr 14:00 Super Session 6

Ms. Felicitas Riedl

Life Science Expert, European Investment Bank

21 Apr 09:15 Super Session 4

Ms. Louise Rosenlund Nielsen

Head of International Development & Partnerships, CopCap

20 Apr 11:00 Super Session 1

Dr. Paul Ross

Director, APC Microbiome Ireland

20 Apr 14:00 Super Session 2

Dr. Jessica Shull

European Lead, Digital Therapeutics Alliance

21 Apr 14:00 Super Session 6

Mr. Gudmundur Fertram Sigurjonsson

Founder, President & CEO, Kerecis

20 Apr 09:30 Opening Plenary

View profile

Mr. Gudmundur Fertram Sigurjonsson

Founder, President & CEO, Kerecis

It is great to be a part of NLSDays to tell the story of Kerecis and network with other companies in the biotech space. I am now more convinced than ever that the groundbreaking developments that are taking place in the Nordic region truly will make a great impact on our lives,”

 

Residual fish skin has formed the basis of Iceland’s fastest growing company, Kerecis. Skin from cold water fish is naturally rich in Omega-3, which accelerates wound healing and is also ideal for human tissue as there is no risk of infection between such cold-water fish and humans. The company’s vision is to become the world leader in tissue regeneration by sustainably harnessing nature’s own remedies. www.kerecis.com

 

Opening Plenary 20 April 9:30 CET

Opening Plenary

Dr. Patrick Sobocki

Investment Manager, Industrifonden

21 Apr 11:00 Super Session 5

Ms. Helena Strigård

Director General, SwedenBIO

20 Apr 09:30 Opening Plenary

Dr. Christina Trojel-Hansen

CEO and Co-Founder - Oscine Therapeutics, in Residence - Arch Venture Partners

21 Apr 09:15 Super Session 4

Dr. Gupta Udatha

Project Coordinator, DIGI-B-CUBE

21 Apr 11:00 Super Session 5